Zentalis Pharmaceuticals (ZNTL) Receivables - Other (2019 - 2023)

Zentalis Pharmaceuticals has reported Receivables - Other for 5 years, with the latest figure at $7.9 million in Q1 2023.

• For the quarter ending Q1 2023, Receivables - Other rose 236.8% year-over-year to $7.9 million; the trailing twelve-month figure through Mar 2023 stood at $7.9 million (up 236.8% YoY), and the FY2022 full-year result was $5.9 million, up 147.53% from the prior year.
• Receivables - Other for Q1 2023 stood at $7.9 million, up from $5.9 million in the prior quarter.
• The five-year high for Receivables - Other was $82.0 million in Q1 2020, with the low at $100000.0 in Q2 2020.
• Average Receivables - Other over 5 years is $9.5 million, with a median of $2.4 million recorded in 2021.
• Year-over-year, Receivables - Other jumped 10150.0% in 2020 and tumbled 92.43% in 2022.
• Tracing ZNTL's Receivables - Other over 5 years: stood at $200000.0 in 2019, then slumped by 50.0% to $100000.0 in 2020, then jumped by 2273.0% to $2.4 million in 2021, then soared by 147.53% to $5.9 million in 2022, then soared by 34.63% to $7.9 million in 2023.
• The last three Receivables - Other figures came in at $7.9 million (Q1 2023), $5.9 million (Q4 2022), and $3.2 million (Q3 2022), per Business Quant data.

Peer Comparison